ARCT (Arcturus Therapeutics Holdings) Moat Score: 5/10 (As of Jun. 28, 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
54 GF Score
Price $6.86
GF Value $4.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings Moat Score?

Arcturus Therapeutics Holdings ARCT +0.95% 54 Moat Score is 5 as of Jun. 28, 2026. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.41 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,402 Biotechnology companies, Arcturus Therapeutics Holdings ranks better than 96.72% on this metric.

Arcturus Therapeutics Holdings has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Arcturus Therapeutics Holdings has Narrow Moat: Arcturus Therapeutics has a solid narrow moat based on its valuable intellectual property and R&D capabilities in RNA therapeutics. However, the biotech industry is highly competitive, and regulatory barriers are significant but not exclusive.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Arcturus Therapeutics Holdings might have Narrow Moat - Solid narrow moat.

Arcturus Therapeutics Holdings  (NAS:ARCT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Arcturus Therapeutics Holdings Moat Score Related Terms

ARCT vs YDES, RNAC, RNA: Moat Score Comparison

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcturus Therapeutics Holdings Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Moat Score falls into.


ARCT
54GF Score
Arcturus Therapeutics Holdings Inc ARCT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Arcturus Therapeutics Holdings (ARCT) has a Moat Score of 5 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Arcturus Therapeutics Holdings ranks #46 out of 1402 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Arcturus Therapeutics Holdings' Moat Score too high?
Arcturus Therapeutics Holdings' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Arcturus Therapeutics Holdings' value of 5 is 150% above this industry median. Based on the distribution chart, Arcturus Therapeutics Holdings ranks #46 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Moat Score compare to YDES and RNAC?
According to the Biotechnology industry distribution chart, Arcturus Therapeutics Holdings ranks #46 out of 1402 companies for Moat Score. This places Arcturus Therapeutics Holdings in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Arcturus Therapeutics Holdings' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcturus Therapeutics Holdings's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcturus Therapeutics Holdings's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $6.86 — trading 55.6% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Moat Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $6.86 is trading 55.6% above its estimated GF Value™ of $4.41. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • Moat Score: 5
  • GF Value™: $4.41 vs. price of $6.86 (55.6% above fair value)
  • GF Score™: 54/100 with 4 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1402)

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score

Get the complete analysis for ARCT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.86
Price
$4.41
GF Value